Cancer Institute (WIA) launches lab for cervical cancer screening

Persistent infection with high-risk HPV has been established to be the principal cause of cervical cancer in women, with HPV implicated in greater than 99 per cent of cervical cancers worldwide. It can take 10 to 15 years or longer for cervical cancer to develop so regular screening to know a woman’s individual risk and finding disease early, before cancer develops, is an important prevention strategy.

The molecular lab launch event which discussed at length the need for screening of cervical cancer saw the presence of dignitaries namely Dr J Radhakrishnan, Principal Secretary (Health and Family Welfare), Government of Tamil Nadu, Dr V Shanta, Chairperson, Cancer Institute (WIA), Mr S N Pandey, Managing Director, Chennai Petroleum Corporation and Dr Shravan Subramanyam, Managing Director, Roche Diagnostics India.

India accounts for 20 per cent of world-wide prevalence for cervical cancer, and has an incidence and mortality rate higher than most regions, including South East Asia. More than 1.2 lakh cervical cancer cases are detected in India annually, making it the second leading cause of cancer after breast cancer. Chennai stands fourth among the top registries in India with the highest incidence of cervical cancer in women, according to a report from the ICO HPV Information Centre. According to National Cancer Registry Programme and World Health Organisation, Chennai has reported more of age-adjusted prevalence of the disease.

Dr V Shantha said, “cervical cancer is preventable, hence, adopting a comprehensive approach that includes vaccination, effective screening, early diagnosis and treatment has the potential to reduce the existing mortality relating to this cancer. In India, the absence of organised screening programmes have contributed to this situation. We in Tamil Nadu, however, have implemented a state-wide cancer registry and the Government of TN has been running a state-wide screening programme.”

Under the leadership of Dr V Shanta, Cancer Institute (WIA), pioneered prevention of cervical cancer with community screening in Kanchipuram district in 1960-61. With 57 years of expertise in the area of preventive oncology from the institute, she says that “with the launch of this new HPV testing, the institute has added one more first to its credit.”

Speaking at the event, Dr Shravan Subramanyam, Managing Director, Roche Diagnostics India said, “Roche Diagnostics with its molecular HPV DNA testing has been globally partnering with governments and private health institutions to enable prevention and early diagnosis of cervical cancer. In India and especially in Tamil Nadu, where the incidence of this completely preventable cancer is high, with the cancer institute’s progressive molecular testing lab, we can start making a difference to women’s lives. That this facility is going to be available to women across the state, especially for women in vulnerable communities makes it fulfilling. I am confident that our discussions with the forward-thinking TN government will help us implement HPV DNA-based cervical cancer screening across the state to help prevent cervical cancer and save valuable lives.”

Currently, the most commonly used method of screening employed in the developed world is cytology based pap smears, which has contributed considerably to reducing incidence of, and mortality from, cervical cancer. Another screening method is HPV DNA testing, which has higher sensitivity vis-à-vis cytological screening, and can detect more precancerous lesions than cytology. Hence, it can be implemented with longer intervals between screenings and can potentially help in reducing cervical cancer incidence, and averting more deaths from the disease.

Source:http://www.expressbpd.com/healthcare/happening-now/cancer-institute-wia-launches-lab-for-cervical-cancer-screening/407850/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more